Envoy Medical, Inc. (COCH) · Oct 27, 2026 · Other events

Envoy Medical reverse split secures Nasdaq compliance, buys no new runway

1-for-10 reverse split — 1-for-10 ratio; $1.00 minimum bid requirement

Envoy Medical’s reverse stock split addresses Nasdaq’s $1 minimum bid rule, but adds no funding or new Acclaim milestone.

Envoy Medical is a clinical-stage hearing-technology company trying to move its fully implanted Acclaim cochlear implant through a rolling FDA application and pivotal trial; it submitted the second of four planned PMA modules on October 12, with the final clinical module targeted for the second quarter of 2027.

This filing fixes a listing problem, not the product-development story. The company implemented a 1-for-10 reverse split to address Nasdaq’s $1.00 minimum bid requirement. It consolidates shares and proportionately adjusts warrants, convertibles, and equity-plan shares, while leaving the authorized share count unchanged. 〔0〕

The action is largely procedural and already known. Stockholders approved the reverse-split authority on October 12, and the company announced the specific 1-for-10 ratio and October 26 effective date on October 22. 〔1〕 That makes this 8-K confirmation rather than a new financing, clinical result, FDA milestone, or change to the Acclaim timeline.

It preserves access to Nasdaq but does not strengthen operating liquidity. The split may help the company remain listed and potentially broaden the pool of institutions able to hold the stock, but the filing provides no proceeds, runway extension, or evidence that the Acclaim program is closer to approval. The separate compliance risk remains relevant: the company’s proxy identified November 16, 2026 as the deadline to regain compliance, with delisting proceedings possible if it failed.

Bottom line: This is a necessary capital-markets housekeeping step that protects the company’s listing status, but it does not advance Envoy Medical’s core Acclaim commercialization story. Its significance is therefore limited and mostly already reflected in the prior shareholder approval and announcement.

What to watch next

Nasdaq compliance deadline, November 16, 2026

Original filing on SEC EDGAR

More Envoy Medical, Inc. news

Envoy Medical reverse split secures Nasdaq compliance, buys no new runway | COCH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.